The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.~Secondary objectives include:~To compare response rate of patients in both treatment arms~To compare overall survival of patients in both treatment arms~To compare toxicity in both treatment arms~To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.